Zobrazeno 1 - 10
of 978
pro vyhledávání: '"D J, Williamson"'
Publikováno v:
British Medical Journal (Clinical Research Edition), 1985 Jan . 290(6464), 326-326.
Externí odkaz:
https://www.jstor.org/stable/29518094
Publikováno v:
The British Medical Journal, 1963 Oct . 2(5364), 1070-1070.
Externí odkaz:
https://www.jstor.org/stable/25396088
Publikováno v:
Perspectives in Public Health; September 1912, Vol. 33 Issue: 9 p408-415, 8p
Autor:
D. S. Shah, D. J. Williamson
Publikováno v:
Clinical and Experimental Dermatology. 35:e90-e93
Autor:
Kynigopoulou, Zoi1 (AUTHOR) kynigopoulou.zoi@gmail.com, Shelley, Sarah L.1 (AUTHOR), Williamson, Thomas E.2 (AUTHOR), Brusatte, Stephen L.1 (AUTHOR) kynigopoulou.zoi@gmail.com
Publikováno v:
PLoS ONE. 10/25/2024, Vol. 19 Issue 10, p1-55. 55p.
Autor:
Peter S. Macdonald, R A Qasabian, Arthur D. Conigrave, C. G. Schyvens, Owe-Young R, D J Williamson
Publikováno v:
British Journal of Pharmacology. 126:103-110
1. We confirmed that endothelium-independent contraction of the rabbit pulmonary artery (RPA) is mediated through both an endothelin A (ET(A)R) and endothelin B (ET(B2)R) receptor. 2. The response of endothelium-denuded RPA rings to endothelin-1 (ET-
Autor:
L.L. Wallman, A. Sturgess, Christopher S. Hayward, Peter S. Macdonald, R. Penny, D J Williamson, P. Rogers
Publikováno v:
Circulation. 94:477-482
Background Inhaled nitric oxide (NO) is a selective pulmonary vasodilator that reduces pulmonary vascular resistance (PVR) in patients with primary pulmonary hypertension. Their responses to inhaled NO predict their responses to other vasodilators, s
Publikováno v:
Psychopharmacology. 126:50-54
We studied the effect of acute (1 day) and subacute (16 days) administration of the new antidepressant, nefazodone (400 mg daily), and the selective serotonin re-uptake inhibitor (SSRI), paroxetine (30 mg daily), on the sleep polysomnogram of 37 heal
Publikováno v:
Australian and New Zealand Journal of Medicine. 26:150-153
Publikováno v:
International Clinical Psychopharmacology. 10:215-220
Thirty drug-free depressed patients underwent double-blind, placebo-controlled, neuroendocrine testing with the serotonin (5-HT) releasing agent d-fenfluramine prior to receiving treatment with a selective serotonin reuptake inhibitor (SSRI) for 8 we